Celsion Corporation (CLSN) Getting Somewhat Favorable Media Coverage, Analysis Shows
News articles about Celsion Corporation (NASDAQ:CLSN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celsion Corporation earned a news impact score of 0.24 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 50.1480853484614 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Celsion Corporation (NASDAQ: CLSN) – Will Shareholder Love To Invest in This Stock? – Alpha Beta Stock (alphabetastock.com)
- Sector NEWS Alert:: Celsion Corporation (NASDAQ:CLSN), Scorpio Tankers Inc. (NYSE:STNG), Gaming and Leisure … – The Stock Street (press release) (thestreetpoint.com)
- Celsion (CLSN) Files Immunotherapy Clinical Protocol for Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian … – StreetInsider.com (streetinsider.com)
- Celsion Corporation (CLSN) noted a price change of 6.00% and Charles River Laboratories International, Inc. (CRL … – Stocks Gallery (stocksgallery.com)
- The Markets Are Undervaluing these stock’s: Celsion Corporation, (NASDAQ: CLSN), SSR Mining Inc., (NASDAQ … – Stocks In The News (press release) (tradingnewsnow.com)
Celsion Corporation (NASDAQ CLSN) traded up $0.12 during midday trading on Tuesday, reaching $2.12. The company had a trading volume of 6,094,500 shares, compared to its average volume of 1,423,527. Celsion Corporation has a 1-year low of $1.24 and a 1-year high of $12.60.
Celsion Corporation (NASDAQ:CLSN) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.14). Celsion Corporation had a negative net margin of 4,440.60% and a negative return on equity of 276.51%. equities analysts anticipate that Celsion Corporation will post -2.56 EPS for the current fiscal year.
A number of research analysts have recently commented on CLSN shares. Zacks Investment Research upgraded Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, August 29th. Maxim Group upgraded Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Celsion Corporation currently has an average rating of “Hold” and an average target price of $12.63.
TRADEMARK VIOLATION NOTICE: “Celsion Corporation (CLSN) Getting Somewhat Favorable Media Coverage, Analysis Shows” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/celsion-corporation-clsn-getting-somewhat-favorable-media-coverage-analysis-shows/1703502.html.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.